EBS 14.55 -0.07 / Emergent Biosolutions FDA | Benzinga

Monday, January 09, 2012

Financial Breakfast: Morning News Summary for January 9, 2012 (ANF, BMY, Earnings, EBS, INHX, INSP, MR, News, NFLX, SPRD, TRV, Futures, Guidance, Upgrades, Commodities, Downgrades, Forex, Technicals, FDA, M&A, Events, Global, Econ #s, Economics, Pre-Market Outlook, Markets, Analyst Ratings, Tech, Trading Ideas, General / Mon, 08:26am)

Wednesday, December 28, 2011

Emergent Announces Plans for TRU-016 Program Following Termination of Collaboration with Abbott (ABT, EBS, News, FDA / Wed, 08:00am)
Emergent Initiates Phase 2 Study of TRU-016 in Combination with Bendamustine in Patients with Relapsed Chronic Lymphocytic Leukemia (EBS, News, FDA / Wed, 08:00am)

Thursday, December 01, 2011

Emergent BioSolutions Receives Orphan Drug Designation for Its TRU-016 Protein Therapeutic for the Treatment of Chronic Lymphocytic Leukemia (EBS, News, FDA / Thu, 08:04am)

Thursday, November 17, 2011

Emergent BioSolutions Initiates Pivotal Clinical Trial Evaluating a Three-Dose BioThrax Regimen for Post-Exposure Prophylaxis (EBS, News, FDA / Thu, 07:53am)

Monday, October 03, 2011

Emergent BioSolutions Receives Award to Supply 44.75 Million Doses of BioThrax to U.S. Government over Five Years (EBS, News, Contracts, FDA / Mon, 07:01am)

Friday, August 26, 2011

Results of Emergent BioSolutions Phase 1a Study on Adjuvanted BioThrax Anthrax Vaccine Published in the Journal Vaccine (EBS, News, FDA / Fri, 06:53am)

Wednesday, August 17, 2011

Emergent Announces Initiation of a Phase 1b/2 Study of TRU-016 in Combination with Rituximab and Bendamustine in Subjects with Relapsed - Indolent Lymphoma (EBS, News, FDA / Wed, 07:02am)

Thursday, June 09, 2011

Emergent BioSolutions' Investigational Anthrax Vaccine, NuThrax, Granted Fast Track Designation (EBS, News, FDA / Thu, 02:40pm)

Friday, February 25, 2011

Emergent BioSolutions Announces that European Parliament Expresses Support for Rapid Development of New TB Vaccine (EBS, News, FDA / Fri, 11:52am)